Victoza
(Liraglutide)ApprovedPeptide
Novo NordiskLiraglutide is used to help people with type 2 diabetes control their blood sugar levels, and it's also used to help with weight loss in people who are overweight or obese.[2] Victoza is currently approved and in use across 63 indications[4].[1]
Victoza is one of 1274 small molecule programs targeting Insulin resistance. It is currently in Approved.
63
Indications
371
Total Trials
13
Active Trials
1,273
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 62 indications
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Lovaza
AstraZenecaPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes53 trials
Show 50 more trials
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
Completed·—·Phase 2·NCT01399645·35 enrolled
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04146155·200 enrolled
The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
Unknown status·—·Phase 2·NCT03426085·44 enrolled
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
Active, not recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT05313529·396 enrolled
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1/2·NCT02960659·24 enrolled
Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
Terminated·—·Phase 4·NCT01597531·1 enrolled
Liraglutide30 trials
Show 27 more trials
Type 2 Diabetes Mellitus11 trials
Show 8 more trials
Weight loss10 trials
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
Unknown status·GGeneral Committee of Teaching Hospitals and Institutes, Egypt·N/A·NCT05285397·60 enrolled
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
Not yet recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 4·NCT07301437·120 enrolled
Show 7 more trials
Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg
Completed·—·N/A·NCT03534310·75 enrolled
Obesity9 trials
Show 6 more trials
LIROH - Liraglutide for Obesity in HIV
Recruiting·—·Phase 4·NCT06438146·40 enrolled
62 more indications
Diabetes Mellitus6 trials
Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus
Completed·—·N/A·NCT02036372·150 enrolled
Type 1 Diabetes5 trials
Show 2 more trials
52 Week Trial of Liraglutide in Type 1 Diabetes
Completed·—·Phase 4·NCT01787916·15 enrolled
Obese Patients4 trials
Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT04325581·16 enrolled
Type 1 Diabetes Mellitus4 trials
Polycystic Ovary Syndrome3 trials
Diabetes3 trials
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data
Completed·—··NCT05162183·3,474 enrolled
Replication of the LEADER Diabetes Trial in Healthcare Claims
Completed·—··NCT03936049·168,690 enrolled
Binge Eating2 trials
Overweight2 trials
Coronary Artery Disease2 trials
Hyperglycemia2 trials
Cardiovascular2 trials
Cardiovascular Disease1 trial
Infertility1 trial
Gestational Diabetes1 trial
Obstructive Sleep Apnea1 trial
Efficacy and Safety1 trial
Congestive Heart Failure1 trial
Diabetic Neuropathy1 trial
Treatment of Diabetic Neuropathy With Liraglutide
Completed·—·N/A·NCT02138045·39 enrolled
Ischemic Cardiomyopathy1 trial
Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy
Unknown status·—·N/A·NCT02930265·400 enrolled
Obstructive Sleep Apnoea1 trial
Insulin Secretion1 trial
Hypogonadism1 trial
Concentration1 trial
AIN1 trial
Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)
Unknown status·—·Phase 4·NCT02055014·72 enrolled
Weight Management1 trial
Type 2 Diabetic Patients1 trial
Double-blind1 trial
Fatty Liver1 trial
Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
Terminated·—·Phase 4·NCT02721888·127 enrolled
Tolerance1 trial
Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?
Unknown status·—·Phase 2·NCT01845259·103 enrolled
Gastrointestinal1 trial
Local1 trial
Transient Ischemic Attack1 trial
Fatty Liver Disease1 trial
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
Unknown status·—·Phase 4·NCT06501326·102 enrolled
Gastroesophageal Reflux1 trial
Heart Failure1 trial
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
Completed·—·Phase 2·NCT01800968·300 enrolled
Maturity-Onset Diabetes of the Young1 trial
Patient Preference1 trial
Parkinson's Disease1 trial
Safety and Efficacy of Liraglutide in Parkinson's Disease
Completed·—·Phase 2·NCT02953665·63 enrolled
Coronary Stenosis1 trial
Safety and Efficacy1 trial
Metabolic Syndrome1 trial
Psoriatic Arthritis1 trial
MODY1 trial
Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters
Unknown status·—·N/A·NCT02490176·50 enrolled
Neuropathic Pain1 trial
Sleep Disorder1 trial
A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks
Completed·—·Phase 1/2·NCT01832532·34 enrolled
Unspecified2 trials
Effects of Glucagon Like Peptide-1 on No-reflow
Unknown status·—·N/A·NCT02507128·190 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 25, 2010
VICTOZA
NDA NDA022341
Dec 23, 2014
SAXENDA
NDA NDA206321
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Victoza drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Liraglutide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glucagon-Like Peptide 1 Receptor Agonist[3]
- Modality
- Peptide[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
Jan 9, 2037
Earliest patent expiration — generic entry possible after this date